297-88-1

Basic information

• Product Name: METHADONE
• Synonyms: methadone base;6-(Dimethylamino)-4,4-diphenyl-3-heptanone DL-mixture;USSIQXCVUWKGNF-UHFFFAOYSA-N
• CAS NO: 297-88-1
• Molecular Formula: C21H27NO
• Molecular Weight: 309.45
• Mol File: 297-88-1.mol
• Article Data: 8

Chemical Properties

• Melting Point: 80°C
• Boiling Point: 449.71°C (rough estimate)
• Appearance: /
• Density: 1.0350 (rough estimate)
• Refractive Index: 1.5614 (estimate)
• CAS DataBase Reference: METHADONE(CAS DataBase Reference)
• NIST Chemistry Reference: METHADONE(297-88-1)
• EPA Substance Registry System: METHADONE(297-88-1)

Safety Data

• RIDADR: 1544
• HazardClass: 6.1(b)
• PackingGroup: III
• Hazardous Substances Data: 297-88-1(Hazardous Substances Data)

Usage

General Description

Methadone is a synthetic opioid medication extensively used for the treatment of opioid addiction, such as heroin and narcotic painkillers. The chemical formula for methadone is C21H27NO. It effectively prevents withdrawal symptoms by acting on the same opioid receptors in the brain that opioids do but without the euphoria or harmful side effects. Methadone is additionally utilized for chronic pain management. Despite its therapeutic use, it carries risks such as respiratory depression, dependence, and potential for overdose if used improperly, highlighting the need for careful monitoring and regulation of its use.

Upstream product

• 86-29-3 Diphenylacetonitrile 
• 10467-10-4 ethylmagnesium iodide 
• 125-79-1 (R,S)-2,2-diphenyl-4-dimethylaminopentanenitrile 
• 76-99-3 Methadone 
• 7576-16-1 (R)-(-)-2,2-diphenyl-4-dimethylaminopentanenitrile 
• 925-90-6 ethylmagnesium bromide 
• 1095-90-5 methadone hydrochloride 
• 7576-08-1 (S)-(+)-2,2-diphenyl-4-dimethylaminopentanenitrile 
• 5967-73-7 (R)-methadone hydrochloride 
• 6336-52-3 1,1-diphenylbutan-2-one 
• 53309-35-6 (2-chloro-1-methyl-ethyl)-dimethyl-amine 

Downstream Products

• 15284-15-8 (+)-Methadone hydrochloride 
• 30223-73-5 (R,S)-2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine 
• 13957-55-6 recipavrin 

Relevant articles and documents

Simultaneous chiral separation of tramadol and methadone in tablets, human urine, and plasma by capillary electrophoresis using maltodextrin as the chiral selector

The stereoselective analysis and separation of racemic drugs play an important role in pharmaceutical industry to eliminate the unwanted isomer and find the right therapeutic control for the patient. Present study suggests a maltodextrin-modified capillary electrophoresis method for a single‐run chiral separation of two closely similar opiate pain relief drugs: tramadol (TRA) and methadone (MET). The best separation method possible for the both enantiomers was achieved on an uncoated fused‐silica capillary at 25°C using 100 mM phosphate buffer (pH 8.0) containing 20% (w v?1) maltodextrin with dextrose equivalent of 4–7 and an applied voltage of 16 kV. Under optimal conditions, the baseline resolution of TRA and MET enantiomers was obtained in less than 12 minutes. The relative standard deviations (n = 3) of 20 μg mL?1 TRA and MET were 2.28% and 3.77%, respectively. The detection limits were found to be 2 μg mL?1 for TRA and 1.5 μg mL?1 for MET. This method was successfully applied to the measurement of drugs concentration in their tablets, urine, and plasma samples.

Non-Racemic Mixtures of Various Ratios of D- and L-methadone and Methods of Treating Pain Using the Same

Non-racemic mixtures of D- and L-methadone containing a ratio ranging from about 2.5:1 to about 3.5:1 by weight of D-methadone to L-methadone, such as for example about 2.9:1 to about 3.1:1 by weight of D-methadone to L-methadone, or about 3:1 by weight of D-methadone to L-methadone, have been found to exhibit surprising and unexpected beneficial results in the treatment of neuropathic pain. Additionally, non-racemic mixtures of D- and L-methadone containing a ratio ranging from about 2.5:1 to about 3.5:1 by weight of D-methadone to L-methadone, about 2.9:1 to about 3.1:1 by weight of D-methadone to L-methadone, or for example about 3:1 by weight of D-methadone to L-methadone, in combination with other non-methadone opioids have been found to exhibit surprising and unexpected beneficial results in the treatment of mixed pain.

(R)-6-(DIMETHYLAMINO)-4,4-DIPHENYLHEPTAN-3-ONE

Methods for producing methadone and its resolution to produce (R)-6-dimethylamino-4,4-diphenylheptan-3-one ((R)- methadone). Such methods producing first the precursor compound 4-(dimethylamino)-2,2-diphenylpentanitrile. Oxidation of 4-(dimethylamino)-2,2-diphenylpentanitrile with ethyl magnesium halide and hydrolysis with of the complex to form 6-dimethylamino-4,4-diphenylheptan-3-one. Resolution to the (R)-isomer is effected by reaction with a bromocamphor salt. Once isolated the (R)-isomer is crystallised.